Does the media prefer ZVRA or TRVI?

In the previous week, Trevi Therapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Trevi Therapeutics and 6 mentions for Zevra Therapeutics. Trevi Therapeutics' average media sentiment score of 1.01 beat Zevra Therapeutics' score of 0.32 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ZVRA or RGC?

Zevra Therapeutics presently has a consensus price target of $27.14, suggesting a potential upside of 128.67%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ZVRA or RGC?

Zevra Therapeutics has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zevra Therapeutics $106.47M 6.62 $83.23M $0.92 12.90 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer ZVRA or RGC?

In the previous week, Zevra Therapeutics had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Zevra Therapeutics and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.77 beat Zevra Therapeutics' score of 0.32 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor PBH or ZVRA?

In the previous week, Zevra Therapeutics had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 6 mentions for Zevra Therapeutics and 5 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.39 beat Zevra Therapeutics' score of 0.32 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prestige Consumer Healthcare 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZVRA or BHC?

In the previous week, Bausch Health Cos had 17 more articles in the media than Zevra Therapeutics. MarketBeat recorded 23 mentions for Bausch Health Cos and 6 mentions for Zevra Therapeutics. Bausch Health Cos' average media sentiment score of 1.04 beat Zevra Therapeutics' score of 0.32 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zevra Therapeutics (ZVRA) Competitors

$11.87 -0.02 (-0.17%)

As of 08/21/2026 04:00 PM Eastern

Compare

ZVRA vs. ATAI, TRVI, RGC, PBH, and BHC

Should you buy Zevra Therapeutics stock or one of its competitors? Zevra Therapeutics's main competitors and comparable companies include Atai Beckley (ATAI), Trevi Therapeutics (TRVI), Regencell Bioscience (RGC), Prestige Consumer Healthcare (PBH), and Bausch Health Cos (BHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zevra Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Atai Beckley currently has a consensus price target of $10.56, suggesting a potential upside of 43.04%. Zevra Therapeutics has a consensus price target of $27.14, suggesting a potential upside of 128.67%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

In the previous week, Atai Beckley and Atai Beckley both had 6 articles in the media. Atai Beckley's average media sentiment score of 0.67 beat Zevra Therapeutics' score of 0.32 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Positive
Zevra Therapeutics	Neutral

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zevra Therapeutics has a net margin of 42.82% compared to Atai Beckley's net margin of -14,938.36%. Zevra Therapeutics' return on equity of 54.54% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Zevra Therapeutics	42.82%	54.54%	34.15%

Zevra Therapeutics has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	669.18	-$660.05M	-$2.18	N/A
Zevra Therapeutics	$106.47M	6.62	$83.23M	$0.92	12.90

Atai Beckley has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

Zevra Therapeutics beats Atai Beckley on 11 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Trevi Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Zevra Therapeutics presently has a consensus target price of $27.14, indicating a potential upside of 128.67%. Trevi Therapeutics has a consensus target price of $27.08, indicating a potential upside of 50.80%. Given Zevra Therapeutics' higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Zevra Therapeutics has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.62	$83.23M	$0.92	12.90
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

In the previous week, Trevi Therapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Trevi Therapeutics and 6 mentions for Zevra Therapeutics. Trevi Therapeutics' average media sentiment score of 1.01 beat Zevra Therapeutics' score of 0.32 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has a net margin of 42.82% compared to Trevi Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Summary

Zevra Therapeutics and Trevi Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Regencell Bioscience?

Zevra Therapeutics (NASDAQ:ZVRA) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Zevra Therapeutics has a net margin of 42.82% compared to Regencell Bioscience's net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Regencell Bioscience	N/A	N/A	N/A

Zevra Therapeutics presently has a consensus price target of $27.14, suggesting a potential upside of 128.67%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

In the previous week, Zevra Therapeutics had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Zevra Therapeutics and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.77 beat Zevra Therapeutics' score of 0.32 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Zevra Therapeutics has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.62	$83.23M	$0.92	12.90
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Summary

Zevra Therapeutics beats Regencell Bioscience on 11 of the 13 factors compared between the two stocks.

How does Zevra Therapeutics compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prestige Consumer Healthcare currently has a consensus price target of $70.75, suggesting a potential upside of 38.02%. Zevra Therapeutics has a consensus price target of $27.14, suggesting a potential upside of 128.67%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

In the previous week, Zevra Therapeutics had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 6 mentions for Zevra Therapeutics and 5 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.39 beat Zevra Therapeutics' score of 0.32 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prestige Consumer Healthcare has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.23	$190.30M	$3.57	14.36
Zevra Therapeutics	$106.47M	6.62	$83.23M	$0.92	12.90

Prestige Consumer Healthcare has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Zevra Therapeutics has a net margin of 42.82% compared to Prestige Consumer Healthcare's net margin of 15.57%. Zevra Therapeutics' return on equity of 54.54% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Zevra Therapeutics	42.82%	54.54%	34.15%

Summary

Zevra Therapeutics beats Prestige Consumer Healthcare on 10 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Bausch Health Cos?

Zevra Therapeutics (NASDAQ:ZVRA) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Zevra Therapeutics has a net margin of 42.82% compared to Bausch Health Cos' net margin of -10.12%. Zevra Therapeutics' return on equity of 54.54% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Zevra Therapeutics presently has a consensus price target of $27.14, suggesting a potential upside of 128.67%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 24.61%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zevra Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bausch Health Cos had 17 more articles in the media than Zevra Therapeutics. MarketBeat recorded 23 mentions for Bausch Health Cos and 6 mentions for Zevra Therapeutics. Bausch Health Cos' average media sentiment score of 1.04 beat Zevra Therapeutics' score of 0.32 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos has higher revenue and earnings than Zevra Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.62	$83.23M	$0.92	12.90
Bausch Health Cos	$10.27B	0.23	$157M	-$2.96	N/A

Summary

Zevra Therapeutics beats Bausch Health Cos on 10 of the 16 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVRA vs. The Competition

Export

Metric	Zevra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$704.89M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	12.90	789.80	272.60	24.24
Price / Sales	6.62	764.50	618.96	99.81
Price / Cash	12.55	96.77	78.62	53.99
Price / Book	3.23	11.89	13.05	6.20
Net Income	$83.23M	$2.81B	$3.47B	$348.59M
7 Day Performance	4.86%	1.77%	2.09%	0.08%
1 Month Performance	-5.19%	3.85%	6.64%	3.88%
1 Year Performance	25.74%	6.56%	25.02%	16.98%

Zevra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVRA Zevra Therapeutics	4.5932 of 5 stars	$11.87 -0.2%	$27.14 +128.7%	+25.7%	$704.89M	$106.47M	12.90	20	Analyst Forecast
ATAI Atai Beckley	3.4127 of 5 stars	$7.26 +0.1%	$10.56 +45.4%	+61.5%	$2.69B	$4.09M	N/A	80	Analyst Revision
TRVI Trevi Therapeutics	3.0395 of 5 stars	$18.46 +1.7%	$27.08 +46.7%	+137.9%	$2.63B	N/A	N/A	20	News Coverage Positive News Options Volume
RGC Regencell Bioscience	0.4645 of 5 stars	$5.45 +4.0%	N/A	-58.6%	$2.59B	N/A	N/A	10	Positive News
PBH Prestige Consumer Healthcare	3.5904 of 5 stars	$51.51 +0.4%	$70.75 +37.4%	-23.2%	$2.43B	$1.09B	14.43	540	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVRA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. ATAI, TRVI, RGC, PBH, and BHC

How does Zevra Therapeutics compare to Atai Beckley?

Summary

How does Zevra Therapeutics compare to Trevi Therapeutics?

Summary

How does Zevra Therapeutics compare to Regencell Bioscience?

Summary

How does Zevra Therapeutics compare to Prestige Consumer Healthcare?

Summary

How does Zevra Therapeutics compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. ATAI, TRVI, RGC, PBH, and BHC

How does Zevra Therapeutics compare to Atai Beckley?

Do analysts recommend ATAI or ZVRA?

Does the media refer more to ATAI or ZVRA?

Do insiders and institutionals hold more shares of ATAI or ZVRA?

Is ATAI or ZVRA more profitable?

Which has higher earnings and valuation, ATAI or ZVRA?

Which has more risk and volatility, ATAI or ZVRA?

Summary

How does Zevra Therapeutics compare to Trevi Therapeutics?

Do analysts prefer ZVRA or TRVI?

Do institutionals & insiders have more ownership in ZVRA or TRVI?

Which has preferable valuation and earnings, ZVRA or TRVI?

Which has more risk & volatility, ZVRA or TRVI?

Does the media prefer ZVRA or TRVI?

Is ZVRA or TRVI more profitable?

Summary

How does Zevra Therapeutics compare to Regencell Bioscience?

Is ZVRA or RGC more profitable?

Do analysts prefer ZVRA or RGC?

Do institutionals and insiders hold more shares of ZVRA or RGC?

Which has more risk and volatility, ZVRA or RGC?

Does the media prefer ZVRA or RGC?

Which has better valuation and earnings, ZVRA or RGC?

Summary

How does Zevra Therapeutics compare to Prestige Consumer Healthcare?

Do institutionals & insiders have more ownership in PBH or ZVRA?

Do analysts recommend PBH or ZVRA?

Does the media favor PBH or ZVRA?

Which has preferable valuation & earnings, PBH or ZVRA?

Which has more risk and volatility, PBH or ZVRA?

Is PBH or ZVRA more profitable?

Summary

How does Zevra Therapeutics compare to Bausch Health Cos?

Which has more volatility & risk, ZVRA or BHC?

Is ZVRA or BHC more profitable?

Do analysts rate ZVRA or BHC?

Do insiders & institutionals hold more shares of ZVRA or BHC?

Does the media prefer ZVRA or BHC?

Which has preferable valuation & earnings, ZVRA or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools